Low‐level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study

Sia, Romond; Plouzeau, Chloé; Godonou, H.; Guingané, Alice Nanelin; Coulibaly, Adama; Somda, Sosthène; Sermé, Abdel Karim; Burucoa, Christophe

doi:10.1111/hel.12551

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Burkina Faso there are several publications on H. pylori epidemiology [1] [2] [3]. We found neither national nor African recommendations on treatment [11].…”

Section: Introductionmentioning

confidence: 57%

See 1 more Smart Citation

Clinical Efficacy of Prolonged First-Line Treatment against Helicobacter pylori in Ouagadougou

Compaore¹,

Some²,

Guingane³

et al. 2022

OJGas

View full text Add to dashboard Cite

Background: Helicobacter pylori (H. pylori) infection is a public health concern. In fact, due to bacterial resistance, treatment strategy is a challenge. It is then more recommended to prolong first-line treatment. In order to be acceptable, the clinical efficacy of treatment must be higher than 90%. Aim: We aimed to assess the outcome of prolonged first-line treatment among adults. Patients and Methods: The study was cross-sectional among adults and patients were treated for H. pylori eradication for the first time during 10 to 14

show abstract

“…In Burkina Faso there are several publications on H. pylori epidemiology [1] [2] [3]. We found neither national nor African recommendations on treatment [11].…”

Section: Introductionmentioning

confidence: 57%

“…Local antimicrobial resistance is the determinant of successful H. pylori treatment [12]. A prospective molecular study attested a low-level primary clarithromycin resistance of H. pylori on 2018 [3]. H. pylori eradication rate after seven days triple therapy was poor (22.3%) in a neighboring country [13].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Prolonged First-Line Treatment against Helicobacter pylori in Ouagadougou

Compaore¹,

Some²,

Guingane³

et al. 2022

OJGas

View full text Add to dashboard Cite

show abstract

“…Antibiotic resistance studies of H. pylori have been reported in Africa [79,[137][138][139][140][141][142][143][144][145] with widespread results. However, these reports come from less than one-third of the countries on the continent.…”

Section: Wg 4: Treatmentmentioning

confidence: 99%

Helicobacter pylori Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group

Smith,

Schulz,

Ugiagbe

et al. 2024

Dig Dis

View full text Add to dashboard Cite

Background: Helicobacter pylori (H. pylori) infection is the most prevalent type of bacterial infection. Current guidelines from different regions of the world neglect specific African conditions and requirements. The African Helicobacter and Microbiota Study Group (AHMSG), founded in 2022, aimed to create an Africa-specific consensus report reflecting Africa-specific issues. Summary: Eighteen experts from nine African countries and two European delegates supported by nine African collaborators from eight other countries prepared statements on the most important African issues in four working groups: (1) epidemiology, (2) diagnosis, (3) indications and prevention, and (4) treatment. Limited resources, restricted access to medical systems, and underdeveloped diagnostic facilities differ from those of other regions. The results of the individual working groups were presented for the final consensus voting, which included all board members. Key Messages: There is a need for further studies on H. pylori prevalence in Africa, with diagnosis hinged on specific African situation. Treatment of H. pylori in the African setting should be based on accessibility and reimbursement, while indication and prevention should be defined in specific African countries.

show abstract

Low‐level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study

Cited by 2 publications

References 7 publications

Clinical Efficacy of Prolonged First-Line Treatment against <i>Helicobacter pylori</i> in Ouagadougou

Clinical Efficacy of Prolonged First-Line Treatment against <i>Helicobacter pylori</i> in Ouagadougou

<i>Helicobacter pylori</i> Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group

Contact Info

Product

Resources

About

Low‐level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study

Cited by 2 publications

References 7 publications

Clinical Efficacy of Prolonged First-Line Treatment against &lt;i&gt;Helicobacter pylori&lt;/i&gt; in Ouagadougou

Clinical Efficacy of Prolonged First-Line Treatment against &lt;i&gt;Helicobacter pylori&lt;/i&gt; in Ouagadougou

<i>Helicobacter pylori</i> Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group

Contact Info

Product

Resources

About

Clinical Efficacy of Prolonged First-Line Treatment against <i>Helicobacter pylori</i> in Ouagadougou

Clinical Efficacy of Prolonged First-Line Treatment against <i>Helicobacter pylori</i> in Ouagadougou